<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Carisoprodol - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚ÜÅE<a href="/dyos-domain/depressants/">Depressants</a> ‚ÜÅE<span>Carisoprodol</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíä Carisoprodol</h1>
        <h2 class="chemical-name">N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate</h2>
        
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Carisoprodol" 
                data-category="Depressants" 
                data-chemical="N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <span class="alt-name">Soma</span>
            <span class="alt-name">Carisoma</span>
            <span class="alt-name">Muscle Relaxer</span>
            <span class="alt-name">Somas</span>
            <span class="alt-name">Dance</span>
            <span class="alt-name">Las Vegas Cocktail</span>
            <span class="alt-name">Somacid</span>
            <span class="alt-name">Rela</span>
            <span class="alt-name">Relaxin</span>
            <span class="alt-name">Painuran</span>
            <span class="alt-name">Soprodal</span>
            <span class="alt-name">Muscol</span>
            <span class="alt-name">Relaxan</span>
            <span class="alt-name">Sanoma</span>
            <span class="alt-name">Carisome</span>
            <span class="alt-name">Flexartal</span>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status prescription">Schedule IV</span>
          <span class="duration medium">4-6 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/Dyo-s-Dubious-Domain/assets/substances/carisoprodol.jpg" alt="Carisoprodol (Soma) tablets" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>Carisoprodol Chemical Structure</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pharmaceutical Tablets</h4>
          <ul>
            <li><strong>Appearance:</strong> Round, white tablets with distinctive scoring</li>
            <li><strong>Markings:</strong> Various imprints depending on manufacturer (SOMA, 350, etc.)</li>
            <li><strong>Size:</strong> Standard pharmaceutical tablet size</li>
            <li><strong>Color:</strong> Typically white, some generic versions may vary</li>
            <li><strong>Texture:</strong> Smooth pharmaceutical coating</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Common Preparations</h4>
          <ul>
            <li><strong>350mg tablets:</strong> Most common prescription strength</li>
            <li><strong>250mg tablets:</strong> Lower strength, less common</li>
            <li><strong>Crushed powder:</strong> For intranasal abuse (dangerous)</li>
            <li><strong>Combination pills:</strong> Often mixed with codeine or aspirin</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†ÔøΩEÔøΩEStreet Concerns</h4>
          <p><strong>Fake Pills:</strong> Counterfeit Soma may contain unknown substances</p>
          <p><strong>Combinations:</strong> Often abused with alcohol, opioids, or benzodiazepines</p>
          <p><strong>Diverted Supply:</strong> Most street carisoprodol is diverted from legitimate prescriptions</p>
          <p><strong>Adulterants:</strong> Fake tablets may contain dangerous fillers or other drugs</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">175-250mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">250-350mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common (Medical)</span>
          <span class="dose-amount">350mg TID</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong/Abuse</span>
          <span class="dose-amount">700-1050mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy/Dangerous</span>
          <span class="dose-amount">1400mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Medical Dosage Information</h4>
        <ul>
          <li><strong>Standard medical:</strong> 250-350mg three times daily with food</li>
          <li><strong>Maximum duration:</strong> 2-3 weeks (addiction risk increases beyond this)</li>
          <li><strong>Elderly patients:</strong> Reduced dosing due to slower metabolism</li>
          <li><strong>Abuse threshold:</strong> Recreational users often take 2-4x medical doses</li>
          <li><strong>Tolerance development:</strong> Rapid, requiring dose escalation</li>
          <li><strong>Lethal dose:</strong> Highly variable, especially dangerous with other depressants</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> Carisoprodol creates rapid physical dependence and dangerous withdrawal syndrome. Never stop abruptly after regular use.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:00</span>
          <span class="effect">Onset - muscle relaxation, mild euphoria</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-3:00</span>
          <span class="effect">Peak - sedation, anxiety relief, euphoria</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+3:00-6:00</span>
          <span class="effect">Plateau - continued relaxation, potential drowsiness</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00-12:00</span>
          <span class="effect">Comedown - gradual return, possible rebound anxiety</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÅETherapeutic/Desired Effects</h4>
          <ul>
            <li>Effective muscle relaxation and spasm relief</li>
            <li>Anxiety reduction and stress relief</li>
            <li>Pain relief (indirect through muscle relaxation)</li>
            <li>Sedation and sleep promotion</li>
            <li>Mild euphoria (contributing to abuse potential)</li>
            <li>Tension release and physical comfort</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùÅENegative Effects</h4>
          <ul>
            <li>Severe drowsiness and cognitive impairment</li>
            <li>Dizziness and coordination problems</li>
            <li>Nausea and gastrointestinal upset</li>
            <li>Headache and confusion</li>
            <li>Rapid tolerance and physical dependence</li>
            <li>Dangerous withdrawal syndrome</li>
            <li>Respiratory depression (especially with other depressants)</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Unique Prodrug Mechanism</h4>
        <p>Carisoprodol functions as a prodrug that is rapidly metabolized to meprobamate, a controlled substance with significant psychoactive properties. While carisoprodol itself has some activity, its primary therapeutic and abuse effects come from its conversion to meprobamate, which acts as a positive allosteric modulator of GABA-A receptors.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor">GABA-A Receptor</span>
            <span class="activity">Positive Allosteric Modulator (via meprobamate)</span>
            <span class="effect">Sedation, anxiolysis, muscle relaxation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">Voltage-Gated Ca¬≤‚Å∫ Channels</span>
            <span class="activity">Modulation</span>
            <span class="effect">Reduced muscle excitability</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">Central Nervous System</span>
            <span class="activity">General CNS Depression</span>
            <span class="effect">Sedation, cognitive impairment</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">Spinal Cord Interneurons</span>
            <span class="activity">Inhibition</span>
            <span class="effect">Muscle relaxation, reduced spasticity</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Rapid Conversion:</strong> CYP2C19 converts carisoprodol to meprobamate within 1-2 hours</p>
          <p><strong>Active Metabolite:</strong> Meprobamate (Schedule IV controlled substance) provides majority of effects</p>
          <p><strong>Carisoprodol Half-life:</strong> 2 hours (parent compound)</p>
          <p><strong>Meprobamate Half-life:</strong> 10 hours (active metabolite)</p>
          <p><strong>Genetic Variability:</strong> CYP2C19 polymorphisms affect conversion rate and effects</p>
          <p><strong>Peak Effects:</strong> 1-2 hours after oral administration</p>
        </div>

        <h4>Dependence and Withdrawal Mechanisms</h4>
        <div class="neurotoxicity-info">
          <p><strong>GABA-A Dependence:</strong> Chronic use leads to downregulation of GABA-A receptors</p>
          <p><strong>Rapid Tolerance:</strong> Receptor desensitization occurs within days of regular use</p>
          <p><strong>Dangerous Withdrawal:</strong> Sudden cessation can cause seizures, similar to alcohol/benzodiazepine withdrawal</p>
          <p><strong>Cross-Tolerance:</strong> With alcohol, benzodiazepines, and other GABA-ergic drugs</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Prodrug Design:</strong> Originally designed to avoid direct GABA activity but metabolizes to controlled substance</li>
          <li><strong>Muscle-Specific Action:</strong> Preferentially affects skeletal muscle tone vs. general sedation</li>
          <li><strong>Rapid Onset:</strong> Effects begin within 30 minutes, contributing to abuse potential</li>
          <li><strong>Metabolic Dependence:</strong> Addiction potential tied to meprobamate conversion</li>
          <li><strong>Combination Synergy:</strong> Dangerously potentiates other CNS depressants</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†ÔøΩEÔøΩESafety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Rapid Dependence:</strong> Physical addiction can develop within 1-2 weeks</li>
            <li><strong>Dangerous Withdrawal:</strong> Can cause life-threatening seizures</li>
            <li><strong>Respiratory Depression:</strong> Especially dangerous with alcohol or other depressants</li>
            <li><strong>Driving Impairment:</strong> Severely affects coordination and reaction time</li>
            <li><strong>Overdose Risk:</strong> Narrow margin between therapeutic and toxic doses</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°ÔøΩEÔøΩESafety Precautions</h4>
          <ul>
            <li><strong>Medical Supervision:</strong> Use only under physician guidance</li>
            <li><strong>Short-term Use:</strong> Maximum 2-3 weeks to avoid dependence</li>
            <li><strong>No Alcohol:</strong> Combination can be fatal</li>
            <li><strong>Tapering Required:</strong> Never stop abruptly if used regularly</li>
            <li><strong>Drug Interactions:</strong> Avoid with other CNS depressants</li>
            <li><strong>Regular Monitoring:</strong> Watch for signs of tolerance and dependence</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Medical Contraindications</h4>
        <p><strong>Do not use if you have:</strong> History of substance abuse, respiratory depression, sleep apnea, liver disease, kidney disease, seizure disorders, or are taking other CNS depressants.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏ÅEDrug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Deadly Combinations</h4>
          <ul>
            <li><strong>Alcohol:</strong> Synergistic CNS depression, respiratory failure, death</li>
            <li><strong>Opioids:</strong> Extreme respiratory depression and overdose risk</li>
            <li><strong>Benzodiazepines:</strong> Dangerous sedation and respiratory depression</li>
            <li><strong>Barbiturates:</strong> Severe CNS depression, high fatality risk</li>
            <li><strong>Other Muscle Relaxants:</strong> Additive effects, overdose potential</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Dangerous</h4>
          <ul>
            <li><strong>Sleep Medications:</strong> Enhanced sedation and impairment</li>
            <li><strong>Antihistamines:</strong> Increased drowsiness and cognitive impairment</li>
            <li><strong>Antipsychotics:</strong> Enhanced sedative effects</li>
            <li><strong>Anticonvulsants:</strong> Potential for dangerous interactions</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Extreme Caution</h4>
          <ul>
            <li><strong>CYP2C19 Inhibitors:</strong> May increase meprobamate levels</li>
            <li><strong>Antidepressants:</strong> May affect metabolism and sedation</li>
            <li><strong>Blood Pressure Medications:</strong> Enhanced hypotensive effects</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏ÅELegal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United States</h4>
            <p>Schedule IV controlled substance - prescription required, penalties for unauthorized possession</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Canada</h4>
            <p>Prescription required - controlled under Food and Drug Act</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United Kingdom</h4>
            <p>Prescription-only medicine (POM) - not controlled but regulated</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Australia</h4>
            <p>Schedule 4 prescription medicine - controlled distribution</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Medical Status</h4>
          <p>Approved for short-term treatment of muscle spasticity and pain. Many countries have restricted or discontinued carisoprodol due to abuse potential and availability of safer alternatives.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1959</span>
          <p>Developed by Wallace Laboratories as a safer alternative to meprobamate</p>
        </div>
        <div class="history-event">
          <span class="year">1959</span>
          <p>FDA approval for muscle spasticity and acute musculoskeletal pain</p>
        </div>
        <div class="history-event">
          <span class="year">1960s-70s</span>
          <p>Widespread medical use as muscle relaxant</p>
        </div>
        <div class="history-event">
          <span class="year">1980s-90s</span>
          <p>Recognition of abuse potential and dependence issues</p>
        </div>
        <div class="history-event">
          <span class="year">2012</span>
          <p>Reclassified as Schedule IV controlled substance in the US</p>
        </div>
        <div class="history-event">
          <span class="year">2007</span>
          <p>European Union banned carisoprodol due to abuse concerns</p>
        </div>
        <div class="history-event">
          <span class="year">2020s</span>
          <p>Growing restrictions worldwide, many countries discontinuing use</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Clinical and Abuse Context</h4>
        <p>Carisoprodol occupies a unique position in medicine - originally designed as a safer muscle relaxant but inadvertently creating a prodrug to a controlled substance. The "Las Vegas Cocktail" (Soma + alcohol) became notorious in abuse circles, leading to increased regulation and medical reconsideration of its therapeutic value.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research & Medical Trends</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Alternative Muscle Relaxants</h4>
          <p>Research into safer alternatives like tizanidine and cyclobenzaprine that don't convert to controlled substances.</p>
        </div>
        
        <div class="research-item">
          <h4>Abuse Potential Studies</h4>
          <p>Ongoing research into the relationship between CYP2C19 genetics and addiction susceptibility to guide prescribing practices.</p>
        </div>
        
        <div class="research-item">
          <h4>Withdrawal Management</h4>
          <p>Studies on safe tapering protocols and medical management of carisoprodol withdrawal syndrome.</p>
        </div>
        
        <div class="research-item">
          <h4>Regulatory Trends</h4>
          <p>Examination of international regulatory responses and effectiveness of restrictions in reducing abuse.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/">SAMHSA</a> - Substance abuse treatment resources</li>
          <li><a href="https://www.asam.org/">ASAM</a> - Addiction medicine guidelines</li>
          <li><a href="https://www.cdc.gov/">CDC</a> - Prescription drug safety information</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Addiction Support</h4>
        <ul>
          <li><a href="https://www.na.org/">Narcotics Anonymous</a> - 12-step recovery program</li>
          <li><a href="https://www.smartrecovery.org/">SMART Recovery</a> - Alternative recovery approach</li>
          <li><a href="https://www.psychologytoday.com/">Psychology Today</a> - Find addiction specialists</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Medical Consultation</h4>
        <ul>
          <li><a href="https://www.healthline.com/">Healthline</a> - Medical information and drug interactions</li>
          <li><a href="https://www.mayoclinic.org/">Mayo Clinic</a> - Comprehensive medical information</li>
          <li><a href="https://www.drugs.com/">Drugs.com</a> - Drug interaction checker</li>
        </ul>
      </div>
    </div>
  </div>

</div>


    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/Dyo-s-Dubious-Domain/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>